The subject of the final panel in the BPI Theater at BIO was how single-use technologies are enabling companies to meet the demand for commercial biomanufacturing capacity. Over the past decade, the industry has been adopting disposable bioreactors and other bioprocessing equipment for clinical manufacturing of biopharmaceuticals. Moderator Dan Stanton began this discussion by asking panelists where the industry stands currently for single-use technologies in making commercial products.
Along with Stanton, the roundtable discussion features John Godshalk (senior consultant, Biologics Consulting Group), Gene Yoshioka (director of manufacturing, Avid BioServices), Steven Hager (senior director of technical support, Catalent Biologics), Shiva Khalafpour (head of commercial, clinical development and manufacturing, Lonza Pharma & Biotech), and Jie Chen (vice president of chemistry, manufacturing, and controls, Wu Xi Biologics.
Watch the full roundtable discussion below and leave your thoughts or questions on the topic below in the comments.
Life Sciences partnering events company EBD Group discusses the importance of communication, education, and the trials and tribulations of organizing an event with sustainability in mind.
Learn from the brightest minds in bioprocessing!
The BPI US 2024 scientific agenda includes 200+ of the industry's top scientists to present the latest updates on how to improve efficiencies across all phases of biopharmaceutical development and production.